Self-assembly of DNA nanospheres with controllable size and self-degradable property for enhanced antitumor chemotherapy

Controllable size, self-degradability and targeting property are important for a precise improvement of anti-cancer effects and reduction of side effects of drug vehicles. Here, a series of DNA nanospheres with controllable size and self-degradation ability were constructed through the hybridization of two i-motif strands and two linker strands for targeted cancer therapy. DNA nanospheres with different sizes were fabricated by regulating the linker sequence, and their pH-responsive self-degradation property was realized by the introduction of the i-motif strand. Moreover, the ZY11 aptamer was introduced to endow the DNA nanospheres with targeting property toward SMMC-7721 cancer cells. The results revealed that the appropriate size of DNA nanospheres (80 nm) highly promoted the internalization by mammalian cells. The results of DLS, AFM and CD spectra showed that the DNA nanospheres were stable in a physiological environment but they self-degraded in a slightly acidic environment due to the existence of the i-motif strand. Moreover, the fluorescence of DOX@AP-NSs2 was triple at pH = 5.0 than at pH = 7.4, which further confirmed the pH-responsive drug release performance. The above results proved that the use of DOX@AP-NSs2 is a promising approach to accelerate the rapid release of drugs into the tumors and avoid drug leakage into the normal tissue. The results at a cellular level and in vivo confirmed the pH-responsive targeted antitumor effect. Hence, the novel DNA nanospheres with controllable size and self -degradable property represent a potential tool for targeted drug delivery and cancer therapy.

Automated summary

Controllable size and self-degradability of DNA nanospheres were achieved by hybridization of i-motif and linker strands. The size of DNA nanospheres was regulated by the linker sequence, and their self-degradation ability was pH-responsive due to the i-motif strand. The introduction of ZY11 aptamer allowed for targeting of SMMC-7721 cancer cells.